Li et al. indicated that in a group of patients with advanced non-small cell lung cancer, ERCC1-negative had better progression-free survival (PFS) (p = 0.016) and overall survival (OS) (p = 0.030) in comparison with positive patients [36]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.